DTZ
0.027
68.8%
CTD
2.88
-82.1%
VR8
0.027
42.1%
REG
4.19
-28.9%
RAP
0.028
40%
CLA
0.004
-20%
STG
0.16
39.1%
GTN
0.2
-20%
KAO
2.43
31.4%
R8R
0.12
-20%
MXI
2.24
31%
TMK
0.115
-17.9%
CAN
0.005
25%
EV1
0.01
-16.7%
DTM
0.012
20%
EXT
0.005
-16.7%
MEM
0.006
20%
PL9
0.005
-16.7%
BCC
0.066
17.9%
TZL
0.025
-16.7%
PVT
0.02
17.6%
MGU
0.006
-14.3%
AUV
0.007
16.7%
NHU
0.077
-13.5%
RFT
0.007
16.7%
M4M
0.007
-12.5%
C29
0.022
15.8%
AMS
0.016
-11.1%
GUL
0.083
15.3%
CND
0.016
-11.1%
AGD
0.155
14.8%
FEG
0.12
-11.1%
ITS
0.275
14.6%
IBX
0.008
-11.1%
KTA
0.008
14.3%
IMA
0.016
-11.1%
FMN
0.17
13.3%
REZ
0.008
-11.1%
AUR
0.018
12.5%
LIN
0.682
-10.9%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Interviews

As artificial intelligence reshapes investment markets, the value of human judgement, experience and active management remains critical. Argo Investments (ASX:ARG), one of Australia’s oldest listed investment companies, is navigating this changing environment while maintaining its focus on delivering sustainable income and long-term value for shareholders. Ahead of presenting at the Australian Shareholders’ Association Investor Summit - Future fortunes, human edge, investing in the age of AI - Argo Investments Managing Director Jason Beddow joins Lel Smits from The Stock Network to discuss finding income in a concentrated Australian market, Argo’s move to quarterly dividends and dividend guidance, and the differences between listed investment companies and ETFs. 1. Finding income in a concentrated market Australia’s share market is highly concentrated, particularly among the major banks and resources companies. How does Argo approach finding sustainable income and long-term opportunities within this environment? 2. Quarterly dividends and dividend guidance Argo has moved to paying dividends quarterly and has provided shareholders with dividend guidance. What drove these changes, and what do they mean for investors seeking reliable and sustainable income? 3. Listed investment companies versus ETFs With the continued growth of ETFs, how should investors think about the differences between listed investment companies and passive investment products? Where can active management deliver an advantage? 4. What AI cannot replace AI is becoming increasingly influential in investment research and decision-making. What aspects of investing cannot be replaced by technology, particularly when it comes to face-to-face meetings, experience and human judgement? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Argo Investments (ASX:ARG): Finding income and the human edge in the age of AI
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5BNEEyNDAyQThDNDA5MEU0

Argo Investments (ASX:ARG): Finding income and the human edge in the age of AI

Myopharm is developing treatments for metabolic and inflammatory diseases, led by its Type 2 diabetes drug candidate, TriGlytza®. A recent pre-clinical study achieved its key HbA1c endpoint and reported stronger results than metformin over one month of treatment. Myopharm CEO and Executive Chair Karinza Phoenix joins The Stock Network’s Lel Smits to discuss TriGlytza®, its clinical pathway and the company’s growth strategy. 1. Differentiating TriGlytza® TriGlytza® targets inflammatory pathways linked to pancreatic Beta cell loss. How does it differ from current Type 2 diabetes treatments, and what could it offer patients? 2. FDA and Australian Ethics approval The company has recently received Australian ethics approval and FDA approval what does that mean for the Resilience Phase 2a programme? 3. Preclinical Type 1 Diabetes model You’ve also just released an announcement regarding a preclinical Type 1 Diabetes model. What is the significance of this development? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Myopharm: Advancing TriGlytza® as a new treatment for Type 2 diabetes
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS40NjI5ODZCQUE5NkRBMDI0

Myopharm: Advancing TriGlytza® as a new treatment for Type 2 diabetes

Change Financial (ASX:CCA) has delivered a landmark FY26 result, achieving its maiden full year profit and beating upgraded revenue and EBITDA guidance. Revenue grew 21% while underlying EBITDA surged 17 times, and the company's Vertexon PaaS platform continues to scale rapidly across Australia and New Zealand. Change is positioning itself as a capital-efficient challenger in the payments infrastructure space. Change Financial CEO Tony Sheehan joins The Stock Network's Lel Smits to discuss the milestone result, the scaling of the PaaS platform, and the next phase of growth. 1. Reaching maiden profitability Change has delivered its first full year of profit. What has driven this shift, and what does it signal about the underlying strength of the business model? 2. Scaling the PaaS platform Vertexon PaaS revenue is now the largest contributor to group revenue. What's behind this momentum, and how sustainable is the growth as more clients onboard? 3. The next phase of growth With four new clients being onboarded, another four in final contracting, and gross margins expected to expand further, where do you see the biggest opportunities to accelerate growth in FY27 and beyond? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Change Financial (ASX:CCA): Record results mark maiden full year profit
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4xNUMzRTJBOEYwRTBDOTBD

Change Financial (ASX:CCA): Record results mark maiden full year profit

Imagion Biosystems (ASX:IBX) is advancing a new approach to cancer detection with MagSense®, its non-radioactive, bio-safe molecular MRI imaging agent designed to help clinicians detect cancer earlier and with greater precision. Imagion Biosystems is initially focused on HER2+ breast cancer, using magnetic nanoparticles to identify cancer through advanced MRI imaging and now progressing the MagSense® HER2 Imaging Agent Phase 1b/2 Clinical Trial towards patient enrolment. With key Contract Research Organisation (CRO) work orders signed, investigational product manufacturing complete and discussions with seven prospective U.S. clinical trial sites in process, Imagion Biosystems Chair Bob Proulx joins The Stock Network's Lel Smits to discuss how the company is moving through the critical steps required to launch the study. 1. Preparing for the start of the Phase 2 trial What are the key activities that need to be accomplished before the MagSense® HER2 Phase 1b/2 Clinical Trial can begin? 2. Getting sites ready for patients Once a site is activated what remains to open the study for enrolment? 3. Imagion Biosystems near term expectations With seven prospective U.S. sites being considered, what are your expectations for the near-term? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Imagion Biosystems (ASX:IBX): How MagSense® is moving towards Phase 2 clinical trials
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS43OTZFNzk1NjVDNDVBRjZG

Imagion Biosystems (ASX:IBX): How MagSense® is moving towards Phase 2 clinical trials

Global private debt assets under management reached US$2 trillion by mid-last year, with the broader private credit ecosystem estimated at around US$4 trillion. Pengana Global Private Credit Trust (ASX:PCX) gives Australian investors access to a globally diversified private credit portfolio managed by Pengana Credit. CEO Nehemiah Richardson joins The Stock Network's Lel Smits to discuss why access matters as much as allocation, how to put the strategy into practice and how to separate noise from real credit risk. 1. Why access matters as much as allocation The case for allocating to private credit is well established now but you've said how investors access it matters just as much as whether they allocate. Why? 2. Putting the strategy into practice So how does Pengana Global Private Credit Trust put that into practice? 3. Separating noise from real credit risk There's been a lot of headline noise this year, such as redemptions and software-sector stress. How should investors separate that from real credit risk? 4. Looking ahead What does the opportunity look like from here? 5. Performance How has that translated to performance? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Pengana Global Private Credit Trust (ASX:PCX): Private credit is booming, how you access it matters
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4yQUYyOTAwNjkwNDE5QjlE

Pengana Global Private Credit Trust (ASX:PCX): Private credit is booming, how you access it matters

Michael Hill International (ASX/NZX: MHJ) has just reported record FY26 results, marking a significant step forward in its turnaround strategy and returning the business to growth across Australia, New Zealand and Canada. Under new leadership, the company has simplified the business, sharpened its focus on its two core brands, strengthened its retail execution and renewed its focus on customers. The result has been stronger sales momentum, improved profitability and the restoration of dividends, while Bevilles has also returned to growth. Michael Hill CEO Jonathan Waecker joins The Stock Network’s Lel Smits to discuss the turnaround, the company’s growth strategy and outlook. 1. A turnaround gaining momentum Michael Hill has returned to growth across all three markets, with stronger customer engagement and improved retail execution helping drive the FY26 result. What has changed within the business over the past year, and what do you see as the key factors behind the turnaround? 2. Making jewellery more relevant to customers The company has simplified its strategy and returned to the core strengths of the Michael Hill brand, with a greater focus on customer experience, product and retail execution. How are you thinking differently about the customer and the opportunity to strengthen the brand from here? 3. Building the next phase of growth With momentum building across Australia, New Zealand and Canada, alongside continued growth in online and the recovery of Bevilles, where do you see the biggest opportunities to take Michael Hill forward? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Michael Hill International (ASX/NZX:MHJ): Turnaround delivers record results and renewed growth
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5FN0MwOEIwNDJFMDI5RDhB

Michael Hill International (ASX/NZX:MHJ): Turnaround delivers record results and renewed growth

As AI and computing rapidly reshape how investors access, analyse and act on information, the human edge still remains an important part of long-term investing. Teaminvest Private Group (ASX:TIP) owns the Teaminvest investing platform, bringing together a community of self-directed investors focused on moving beyond speculation through disciplined, long-term investment frameworks. It's investors collectively deploy more than $3 billion into equities, identifying high-quality businesses capable of compounding earnings over many years. Ahead of presenting at the Australian Shareholders’ Association Investor Summit - Future fortunes, human edge, investing in the age of AI - Head of Funds Management and Education, Sanjee Narendran, joins Lel Smits from The Stock Network to discuss the human edge in investing as AI and computing continue to transform markets. 1. The human edge in an AI world AI can process enormous amounts of information in seconds. Where do you believe humans still have the greatest edge when it comes to making successful long-term investment decisions, and where are you utalising AI in the investing process? 2. Beyond the data As AI becomes increasingly capable of analysing businesses, financial data and market trends, what are the qualities that cannot easily be replicated by technology - such as judgement, patience, discipline and understanding people? 3. Social media promotion clip | 30–60 second short answer Ahead of presenting at the Australian Shareholders’ Association Investor Summit, you’ll be discussing the role of humans as AI and computing transform investing. What do you believe will be the biggest human advantage in investing in an AI-driven world? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Teaminvest Private Group (ASX:TIP): Finding the human investing edge in the age of AI
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5GMzY4RDIwMjU1MkMwOTRB

Teaminvest Private Group (ASX:TIP): Finding the human investing edge in the age of AI

Noxopharm (ASX:NOX) has generated new preclinical data showing its Sofra™ technology can activate immune cells in response to dying cancer cells. The study found that dying cancer cells alone did not trigger an immune response, but combining them with Noxopharm’s TLR8-amplifying oligonucleotide drug produced a strong immune activation, reaching seven times the untreated level. The result strengthens the case for using Sofra™ alongside treatments such as chemotherapy and radiotherapy, while moving Noxopharm’s oncology program closer to in vivo proof-of-concept studies. CEO Olivier Laczka speaks with The Stock Network's Lel Smits about activating immune cells against dying cancer cells, producing a substantial immune response, complementing chemotherapy, radiotherapy, checkpoint inhibitors and mRNA vaccines, and moving Sofra™ towards in vivo studies. 1. Activating immune cells against dying cancer cells Dying cancer cells alone did not trigger an immune response, but adding Noxopharm’s TLR8-amplifying drug activated macrophages. How does the drug switch on this immune response? 2. Delivering a seven-fold immune response What does this result tell you about Sofra’s potential? 3. Moving Sofra™ towards in vivo studies The latest research supports combining Sofra™ with treatments that kill cancer cells, including chemotherapy and radiotherapy. What are the next steps towards demonstrating this potential in living models? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Noxopharm (ASX:NOX): New data shows Sofra™ activates immune cells against dying cancer
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS43RjgyNkZCNjkwMkZDMzcz

Noxopharm (ASX:NOX): New data shows Sofra™ activates immune cells against dying cancer

Mesoblast (ASX:MSB, Nasdaq:MESO) has delivered a strong FY2026 result, with Ryoncil® driving a major lift in revenue and the company moving closer to a sustainable commercial model. At the same time, cash discipline has improved while Mesoblast continues to invest in its pipeline and next phase of growth. With Ryoncil® gaining traction, plans to expand into the adult market and its Phase 3 chronic low back pain trial complete, Mesoblast is entering its next stage of growth. Mesoblast CEO and Managing Director Dr Silviu Itescu joins Lel Smits from The Stock Network to discuss the results, Ryoncil® growth and key catalysts ahead. 1. FY26 Financial results highlights You’ve just released your full year results for the 2026 financial year. Can you talk us through the highlights? 2. Ryoncil®: building commercial momentum Ryoncil® generated US$115.2 million in net revenue, with more than 50 U.S. sites onboarded and coverage reaching more than 280 million people. What is driving this growth, and how do you keep the momentum going? 3. Unlocking the adult market Mesoblast is progressing Ryoncil® into adults with severe steroid-refractory acute graft versus host disease, a market three times larger than the paediatric market. How significant could this expansion be, and what are your near term priorities? 4. The next big catalyst The Phase 3 chronic low back pain trial has completed treatment of 350 patients, with results expected in mid-2027. Mesoblast is also advancing its heart failure and next-generation programs. Which upcoming milestone could have the biggest impact on Mesoblast? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Mesoblast (ASX:MSB, Nasdaq:MESO): Strong growth, Ryoncil momentum and unlocking future opportunities
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS42ODgwQ0RBNTY1OTRERDQy

Mesoblast (ASX:MSB, Nasdaq:MESO): Strong growth, Ryoncil momentum and unlocking future opportunities

View More

Get the latest ASX stock market news delivered to your inbox

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy